Thomas Sternberg, MD
Allergy & Immunology · Bowling Green, KYNPI 1467448175
Payments from drug & device makers
Across 479 payments — averaging $35.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Novartis$2K
- AstraZeneca$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Cycle Pharmaceuticals Inc$1K
- Regeneron Healthcare Solutions, Inc.$854
- plus $6K from 33 others
What the payments were for
- Consulting fees$4,43826%
- Speaking & faculty fees$1,2207%
- Food & beverage$11,04065%
- Education$2552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 97 | $3,719 |
| Novartis | 19 | $2,239 |
| AstraZeneca | 68 | $1,922 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $1,419 |
| Cycle Pharmaceuticals Inc | 4 | $1,296 |
| Regeneron Healthcare Solutions, Inc. | 28 | $854 |
| Pharming Healthcare, Inc. | 25 | $679 |
| CSL Behring | 35 | $674 |
| Teva Pharmaceuticals USA, Inc. | 13 | $595 |
| Sanofi | 28 | $571 |
| Biocryst US Sales Co., LLC | 14 | $339 |
| Octapharma USA, Inc. | 9 | $285 |
| Genentech USA, Inc. | 8 | $246 |
| Pfizer | 11 | $238 |
| Amgen(2 entities) | 12 | $230 |
| Boehringer Ingelheim | 12 | $189 |
| Genentech, Inc. | 2 | $174 |
| Grifols USA, LLC | 10 | $166 |
| Kaleo, Inc. | 8 | $145 |
| Biocryst Pharmaceuticals, Inc. | 1 | $123 |
| Alk-abello, Inc | 5 | $108 |
| Regeneron | 1 | $103 |
| Blueprint Medicines Corporation | 4 | $86 |
| Optinose US, Inc. | 4 | $81 |
| AbbVie | 4 | $76 |
| Shire North American Group Inc | 4 | $73 |
| Lilly USA, LLC | 3 | $57 |
| Incyte Corporation | 2 | $41 |
| Mylan Specialty L.p. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $29 |
| Phadia US Inc. | 2 | $28 |
| Verona Pharma, Inc. | 1 | $23 |
| Ionis Pharmaceuticals, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| LEO Pharma Inc. | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,953 in reported general payments places this provider in the 70th percentile of 66 allergy & immunology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlarisCanakinumab/Pf | 12 | $518,029 |
| NucalaMepolizumab | 60 | $386,147 |
| XolairOmalizumab | 48 | $190,892 |
| Dupixent PenDupilumab | 37 | $148,355 |
| TezspireTezepelumab-Ekko | 30 | $136,445 |
| Dupixent SyringeDupilumab | 32 | $136,033 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $119,514 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $114,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $36,481 |
| Spiriva RespimatTiotropium Bromide | 25 | $21,174 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $19,301 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $16,462 |
| Epinephrine | 53 | $14,106 |
| DuleraMometasone/Formoterol | 23 | $13,595 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $12,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlaris | $2,239 | $518,02912 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $3,719 | $436,898128 claims |
| Genentech, Inc.Xolair | $174 | $190,89248 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,922 | $170,57898 claims |
| CSL BehringHizentra | $674 | $119,51413 claims |
| Grifols USA, LLCGamunex-C | $166 | $114,52014 claims |
| Boehringer IngelheimSpiriva Respimat | $189 | $21,17425 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $595 | $14,70646 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $14,10653 claims |
| MerckDulera | $13 | $13,59523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 66 allergy & immunology providers in Kentucky.
Other allergy & immunology in Bowling Green
- James ParkersonBowling Green$8K
- Kourtney GardnerBowling Green$7K
- Indar JhambBowling Green$6K
- Patricia MercerBowling Green$3K
- Lee CloreOwensboro$3.7M
- William GreisnerLexington$1.8M
- James SublettLouisville$1.7M
- Manuel VillarealLakeside Park$533K
- James SublettLouisville$481K
- Stephen PollardLouisville$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.